1990
DOI: 10.1002/mds.870050317
|View full text |Cite
|
Sign up to set email alerts
|

Letters to the editor

Abstract: The Rabbit SyndromeTo The Editor:Two cases of "Rabbit Syndrome" are presented by videotape that demonstrate the typical features of this uncommon condition, which was first described by Villeneuve in 1972 (1). These cases and an additional one (not presented here because consent for publication was not obtained) were identified during the course of a prevalence survey of abnormal movement disorders in 149 schizophrenic inpatients chronically treated with antipsychotics. The results of this survey confirmed a p… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

1997
1997
2020
2020

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 23 publications
(2 citation statements)
references
References 25 publications
0
2
0
Order By: Relevance
“…Therefore, a total of 37 papers were eventually included in the qualitative synthesis ( Figure 1), and the main findings are summarized in Table 1. In more detail, nineteen studies deal with AD or MCI [16,20,23,29,36,[39][40][41][42][43][44][45][46][47][48][49][50][51][52], three with vascular cognitive impairment (VCI) [53][54][55], five with HE [56][57][58][59][60], four with other secondary dementias [61][62][63][64], and six with an unspecified cognitive disorder [65][66][67][68][69][70]. The lowest dose of ALC did not produce changes.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Therefore, a total of 37 papers were eventually included in the qualitative synthesis ( Figure 1), and the main findings are summarized in Table 1. In more detail, nineteen studies deal with AD or MCI [16,20,23,29,36,[39][40][41][42][43][44][45][46][47][48][49][50][51][52], three with vascular cognitive impairment (VCI) [53][54][55], five with HE [56][57][58][59][60], four with other secondary dementias [61][62][63][64], and six with an unspecified cognitive disorder [65][66][67][68][69][70]. The lowest dose of ALC did not produce changes.…”
Section: Resultsmentioning
confidence: 99%
“…Very few studies have assessed the effects of ALC in other secondary dementias. Goetz and colleagues carried out a double-blind placebo-controlled crossover study to investigate ALC at the maximal permitted dose of 45 mg/kg/day for a week on 10 patients with Huntington's disease [61]. The result was that ALC was neither efficient nor toxic, although some patients felt better after ALC, suggesting a subtle improvement that the assessment methods employed in this study could not detect [61].…”
Section: Other Secondary Dementiasmentioning
confidence: 86%